The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours
| Autor: | Peter Tobin, Michael Crawford, Tony Eyers, Michael J. Solomon, Stephen Clarke, Laurent P. Rivory, James J. Gallagher, Soon C. Lee, Sally Aulds, J. Paul Seale |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Colorectal cancer
SN-38 Biology Pharmacology Irinotecan Carboxylesterase Nitrophenols chemistry.chemical_compound medicine Tumor Cells Cultured Humans Pharmacology (medical) Glucuronidase Original Articles Prodrug medicine.disease Antineoplastic Agents Phytogenic chemistry Hydroxyquinolines Camptothecin Glucuronide Colorectal Neoplasms medicine.drug |
| Zdroj: | British journal of clinical pharmacology. 62(1) |
| ISSN: | 0306-5251 |
| Popis: | Irinotecan (CPT-11) is a prodrug that is used to treat metastatic colorectal cancer. It is activated to the topoisomerase poison SN-38 by carboxylesterases. SN-38 is metabolized to its inactive glucuronide, SN-38 glucuronide. The aim of this study was to determine, the reactivation of SN-38 from SN-38 glucuronide by beta-glucuronidase may represent a significant pathway of SN-38 formation.The production of SN-38 from irinotecan and SN-38 glucuronide (2.4, 9.6 and 19.2 microm) was measured in homogenates of human colorectal tumour, and matched normal colon mucosa from 21 patients).The rate of conversion of irinotecan (9.6 microm) was lower in tumour tissue than matched normal colon mucosa samples (0.30+/-0.14 pmol min-1 mg-1 protein and 0.77+/-0.59 pmol min-1 mg-1 protein, respectively; P0.005). In contrast, no significant difference was observed in beta-glucuronidase activity between tumour and matched normal colon samples (4.56+/-6.9 pmol min-1 mg-1 protein and 3.62+/-2.95 pmol min-1 mg-1 protein, respectively, using 9.6 microm SN-38 glucuronide; P0.05). beta-Glucuronidase activity in tumour correlated to that observed in matched normal tissue (r20.23, P0.05), whereas this was not the case for carboxylesterase activity. At equal concentrations of irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production was higher than that formed from irinotecan in both tumour and normal tissue (P0.05). However, at concentrations that reflect the relative plasma concentrations observed in patients, the rate of SN-38 production via these two pathways was comparable.Tumour beta-glucuronidase may play a significant role in the exposure of tumours to SN-38 in vivo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text